The implied message is?
"Lilly's Open Innovation Drug Discovery Program is visionary," said Harry Lander, Ph.D., MBA, president and chief scientific officer of Regen BioPharma, Inc. "They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals.”